摘要
目的探讨Akt抑制剂MK2206对膀胱癌细胞(T24)增殖、凋亡的影响及其作用机制。方法采用CCK-8法检测不同时间、不同浓度(0,1,5,10,20μmol·L-1) MK2206对T24细胞增殖的影响,流式细胞术检测不同浓度MK2206对T24细胞凋亡的影响; Western blotting检测Akt磷酸化蛋白表达情况及GSK-3β/β-catenin通路蛋白的表达水平。结果 CCK-8法检测显示,MK2206对T24细胞增殖活力具有显著的抑制效果(P<0.05),且在0~20μmol·L-1内呈浓度-时间依赖性。流式细胞术检测结果表明,MK2206在作用T24细胞24 h后,能够促进T24细胞凋亡。Western blotting检测显示,p-Akt(ser347)蛋白表达量显著降低(P<0.01);同时,MK2206在对GSK-3β总蛋白表达无明显的影响,P-GSK-3β、β-catenin蛋白表达水平显著降低(P<0.05)。结论 MK2206能够抑制T24细胞增殖,促进其发生凋亡,从而缓解膀胱癌发展进程,其作用机制可能是抑制GSK-3β/β-catenin信号通路。
Objective To explore the effect and mechanism of Akt inhibitor MK2206 on proliferation and apoptosis of T24 cells. Methods The CCK-8 method was used to detect the cell proliferation. Then the effects of different concentrations( 0,1,5,10,20 μmol·L-1) MK2206 on T24 cell apoptosis were tested by flow cytometry. Mealwhile,Western blotting was used to detect the phosphorylation of Akt protein and GSK-3β/β-catenin pathway proteins. Results The result of CCK-8 assay showed that MK2206 had a significant inhibitory effect on the proliferation activity of T24 cells( P<0.05),and the effect was in time-dose dependence manner arranged 0-20 μmol· L-1 concentration. Flow cytometry results showed that the MK2206 could promote apoptosis of T24 cells in 24 h. Comparing to control group,the level of p-Akt( ser347) protein significantly decreased( P<0.01). There was a significantly inhibitory effect on the GSK-3β/β-catenin signaling pathway,which showed the expression of p-GSK-3β and β-catenin proteins was significantly reduced( P<0.05) in the premise of no influence on the expression of GSK-3β. Conclusion MK2206 has inhibited T24 cell proliferation and promoted cell apoptosis via restraining Akt phosphorylation( ser473) and inhibiting the GSK-3β/β-catenin signaling pathway. MK2206 may relieve the tumor development process.
引文
[1]FREDULSPERGER C,HORN D,WEISSFUSS S,et al.Phosphorylation of AKT(Ser473)serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma[J].Int J Cancer,2015,136(12):2775-2785.
[2]BERGES C,BEDKE T,STUEHLER C,et al.Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases tregs[J].J Leukoc Biol,2015,98(6):1091-1105.
[3]CHEN J M,LIAN X L,DU J,et al.Inhibition of phosphorylated Ser473-Akt from translocating into the nucleus contributes to 2-cell arrest and defective zygotic genome activation in mouse preimplantation embryogenesis[J].Dev Growth Differ,2016,58(3):280-292.
[4]HIRAI H,SOOTOME H,NAKATSURU Y,et al.MK2206,an allosteric Akt inhibitor,enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo[J].Mol Cancer Ther,2010,9(7):1956-1967.
[5]NARAYAN R S,FEDRIGO C A,BRANDS E,et al.The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures[J].BMC Cancer,2017,17(1):204.
[6]KNOLLMAN H,GODWIN J L,JAIN R,et al.Muscleinvasive urothelial bladder cancer:an update on systemic therapy[J].Ther Adv Urol,2015,7(6):312-330.
[7]JIA Y L,XIAO Y W,GUAN N W,et al.FOXQ1 promotes cancer metastasis by PI3K/Akt signaling regulation in colorectal carcinoma[J].Am J Transl Res,2017,9(5):2207-2218.
[8]TESTA J R,BELLACOSA A.Comentary-AKT plays a central role in tumorigenesis[J].Proc Natl Acad Sci USA.2001,98(20):10983-10985.
[9]WANG Q,YU W N,CHEN X,et al.Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms[J].Cancer Cell,2016,29(4):523-525.
[10]THOMAS C C,DEAK M,ALESSI D R.High-resolution strcture of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol(3,4,5)-trisphosphate[J].Curr Biol,2002,12(14):1256-1262.
[11]HEN J M,LIAN X L,DU J,et al.Inhibition of phosphorylated Ser473-Akt from translocating into the nucleus contributes to 2-cell arrest and defective zygotic genome activation in mouse preimplantation embryogenesis[J].Dev Growth Differ,2016,58(3):280-292.
[12]XUE G,ROMAO E,MASSI D,et al.Wnt/β-catenin signaling in melanoma:preclinical rationale and novel therapeutic insights[J].Cancer Treat Rev,2016,49(1):1-12.
[13]ALMHANNA K,CUBITT C L,ZHANG S,et al.MK2206,an Akt inhibitor,enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines[J].Cancer Bilo Ther,2013,14(10):14932-14936.
[14]YAP T A,YAN L,PATNAIK A,et al.First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors[J].J Clin Oncol,2011,29(35):4688-4695.
[15]HIRAI H,SOOTOME H,NAKATSURU Y,et al.MK2206,an allosteric Akt inhibitor,enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo[J].Mol Cancer Ther,2010,9(7):1956-1957.
[16]MATSUZAKI S,POULY J L,CANIS M.In vitro and in vivo effects of MK2206 and chloroquine combination therapy on endometriosis antophagy may be required for regrowth of endometriosis[J].Br J Pharmacol,2018,175(10):1637-1653.
[17]MATSUZAKI S,POULY J L,CANIS M.Effects of U0126and MK2206 on cell growth and regrowth of endometriotic stromal cels grown on substates of varying stiffness[J].Sci Rep,2017,7:42939.
[18]WU K,FAN J,ZHANG L,et al.PI3K/Akt to GSK-3β/β-catenin signaling cascade coordinatescell colonization for bladder cancer bone metastasis through regulating ZEB1transcription[J].Cell Signal,2012,24(12):2273-2282.